Wedbush Morgan Believes Levadex and Tempo Now Make MAP Pharmaceuticals (MAPP) an Acquisition Target
Tweet Send to a Friend
Wedbush Morgan maintains an Outperform rating on MAP Pharmaceuticals, Inc. (MAPP), raises price target by $1 to $17.
Wedbush analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Wedbush analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
